Biotrack

What Biotrack does

Biotrack is a Dutch privately held biotechnology company founded in 2011 and headquartered at a fully equipped microbiology laboratory in Leeuwarden, Netherlands. The company has developed and patented C-FISH (Computerized Fluorescence In Situ Hybridization), a molecular detection platform that analyzes microorganisms directly in raw samples without cultivation or amplification, producing simultaneous qualitative, quantitative, and functional activity profiles at single-cell resolution within 20–120 minutes. The platform uses targeted nucleic acid probes for 16s rRNA, 23S rRNA and/or mRNA, combined with proprietary imaging, signal quantification, and data processing, to interrogate microbial populations in their native biological context.

The company's products are positioned across four verticals: healthcare (antimicrobial susceptibility testing, infection diagnostics), environmental testing (water, soil, air microbiome), pharmaceutical and industrial quality control, and biosecurity and safety monitoring. The commercial model is not publicly disclosed: pricing is not listed, no customer logos or case studies are published, no app or API distribution exists, and there are no disclosed funding rounds, investors, or revenue figures. The only documented external relationship is a minor co-location collaboration with NL-Lab at the shared Leeuwarden laboratory.

Biotrack is founder-led (Antoine Engelaar is identified as a founding partner) and operates with a multidisciplinary scientific team spanning microbiology, molecular biology, bioinformatics, engineering, and AI. The company has no disclosed parent entity, no subsidiaries, no M&A activity, no certifications, and no public-facing social media presence beyond its corporate website. Distribution and go-to-market mechanics beyond the website are not described in available source material.

Name

Biotrack

Legal name

Biotrack

Website

https://biotrack.nl

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Biotrack is a Dutch privately held biotech founded in 2011 that has developed and patented C-FISH, a culture-independent molecular detection platform delivering single-cell, qualitative, quantitative, and functional microbial analysis in 20–120 minutes, applied across healthcare, environmental, pharmaceutical, and biosecurity verticals.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics / Microbiology Analysis

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)

Keywords

• Molecular microbiology diagnostics
• Fluorescence in situ hybridization
• Antimicrobial susceptibility testing
• Rapid pathogen detection
• Microbiome analysis platform

Headquarters

HQ city

Leeuwarden

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Marketing channels1 record

Core offering

Biotrack develops and produces compact diagnostic systems based on its patented C-FISH (Computerized Fluorescence In Situ Hybridization) platform, a culture-independent molecular detection technology that analyzes microorganisms directly in raw samples. The platform delivers simultaneous qualitative, quantitative, and functional activity profiles at single-cell resolution with a time-to-result of 20-120 minutes, targeting applications in healthcare diagnostics, pharmaceutical quality control, environmental testing, microbiome analysis, and biosecurity monitoring.

Product overview

Biotrack offers a single unified product platform called C-FISH (Computerized Fluorescence In Situ Hybridization), a patented molecular detection technology for microbiology analysis. The platform provides culture-independent, direct raw sample analysis with single-cell level resolution, generating qualitative, quantitative, and activity profiles of microorganisms. The compact diagnostic systems are applicable across healthcare, healthy living, security, safety, and industry applications including antimicrobial susceptibility testing (AST), infection diagnostics, biosecurity monitoring, microbiome analysis, and environmental surveillance.

Differentiator

Problem solved

Functional benefit

Brands

• C-FISH: Patented molecular detection technology platform for culture-independent, ex-vivo analysis of microorganisms at single-cell level.

Products and services

• C-FISH Platform Patented molecular detection technology platform based on computerized fluorescence in situ hybridization (FISH) principles, enabling culture-independent, ex-vivo analysis of microorganisms directly in raw samples at single-cell level. Delivers simultaneous qualitative, quantitative, and functional activity profiles with a time-to-result of 20-120 minutes, applicable to healthcare diagnostics, pharmaceutical testing, environmental monitoring, microbiome analysis, and biosecurity.

Quantifiable outcome

• Time to result (TTR) reduced to 20-120 minutes compared to conventional culture-based methods that require culturing before analysis

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• NL-LabminorStrategic or Co-development PartnerBiotrack collaborates with NL-Lab at their Leeuwarden facility. NL-Lab appears to be a local laboratory partner working alongside Biotrack's team at their shared microbiological laboratory location.

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Others

• Roche Diagnostics:

Broad incumbents

• Cepheid (Danaher): Developer of the GeneXpert rapid molecular diagnostics platform widely deployed for infectious disease testing. Comparable on rapid, culture-independent molecular detection targeting similar clinical microbiology use cases (UTI, wound, bloodstream infections).
• bioMérieux: Global leader in microbiological diagnostics with a broad portfolio including VITEK (ID/AST), BioBall, and molecular systems. Directly comparable to Biotrack as the incumbent reference standard in clinical microbiology that C-FISH aims to disrupt on speed and functional insight.
• Bruker: Manufacturer of MALDI Biotyper for microbial ID and various molecular biology instruments. Comparable on the laboratory analytical instrumentation side and on microbial identification workflows used by clinical and industrial labs.
• Becton Dickinson (BD): Major diagnostics and life sciences company with the BD MAX and BD Phoenix systems for molecular detection and AST. Comparable as a large incumbent offering competing culture-independent and rapid microbiology workflows to hospital labs.

Direct peers

• T2 Biosystems: Developer of T2 Magnetic Resonance-based direct-from-sample diagnostics for bloodstream and other infections. Comparable as a rapid, culture-independent molecular diagnostic peer targeting similar hospital microbiology applications.
• Q-linea: Swedish diagnostics developer of the ASTar system for rapid AST directly from positive blood cultures. Comparable as a focused European peer attacking the same culture-based microbiology bottleneck with faster, culture-independent workflows.
• Accelerate Diagnostics: Pure-play rapid AST and ID company offering the Accelerate Pheno system that delivers phenotypic susceptibility results in hours. Most directly comparable peer - same niche of faster, function-informed AST and ID for bloodstream and other infections.

Emerging players

• CosmosID: Microbiome analytics and bioinformatics platform offering genomic-based microbial identification and profiling. Comparable on the microbiome analytics and sequencing/bioinformatics side for environmental, clinical, and research microbiome applications that overlap with C-FISH's microbiome use cases.
• Bruker Spatial Biology (MetaSystems-style FISH platforms): Provider of automated FISH imaging and analysis platforms (e.g., MetaSystems). Comparable as a niche FISH-instrument peer using the same core probe-based hybridization chemistry that C-FISH extends to microbial single-cell functional profiling.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biotrack